Volume 123, Issue 2, Pages (August 2002)

Slides:

Advertisements

Similar presentations

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Advertisements

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Interleukin 15 mediates epithelial changes in celiac disease Luigi Maiuri, Carolina Ciacci, Salvatore Auricchio, Virginia Brown, Sonia Quaratino, Marco.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

It's time to bring the best and brightest back to gastroenterology!

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

AGA technical review on irritable bowel syndrome

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Development and validation of a self-report symptom inventory to assess the severity of oral-pharyngeal dysphagia Karen L. Wallace, Sue Middleton, Ian.

Alessio Fasano, Carlo Catassi Gastroenterology

Volume 122, Issue 1, Pages (January 2002)

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Prevalence of Barrett's esophagus in asymptomatic individuals

Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato

Volume 122, Issue 3, Pages (March 2002)

Diagnosis of irritable bowel syndrome

Diagnosis of celiac sprue

Covering the Cover Gastroenterology

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception William E. Whitehead, Olafur.

Leptin, obesity, and liver disease

Volume 122, Issue 1, Pages (January 2002)

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? William E. Whitehead, Olafur.

Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick

Psychiatric disorders among veterans with hepatitis C infection

Volume 122, Issue 7, Pages (June 2002)

Volume 124, Issue 4, Pages (April 2003)

Spreading and focusing of gluten epitopes in celiac disease

Liver fibrosis in overweight patients

Appendectomy is followed by increased risk of Crohn's disease

Volume 123, Issue 2, Pages (August 2002)

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Volume 123, Issue 2, Pages (August 2002)

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C Chi–Jen Chu, Munira Hussain,

Volume 120, Issue 3, Pages (February 2001)

Volume 122, Issue 7, Pages (June 2002)

Volume 124, Issue 1, Pages (January 2003)

Volume 121, Issue 4, Pages (October 2001)

Prevalence of Barrett's esophagus in asymptomatic individuals

Volume 120, Issue 4, Pages (March 2001)

Volume 123, Issue 2, Pages (August 2002)

Volume 122, Issue 7, Pages (June 2002)

Alessio Fasano, Carlo Catassi Gastroenterology

Volume 119, Issue 1, Pages (July 2000)

Volume 122, Issue 7, Pages (June 2002)

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug–Induced Clinical Relapse in Patients With Inflammatory Bowel Disease Ken Takeuchi, Simon.

AGA technical review on nonalcoholic fatty liver disease

Polycystic ovary morphology: age-based ultrasound criteria

AGA technical review on celiac sprue

Psychiatric disorders among veterans with hepatitis C infection

Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease Francesco S. Facchini, Nancy.

Volume 124, Issue 7, Pages (June 2003)

Image of the month Gastroenterology

Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome Claudia I. Reinders, Max Herulf, Tryggve Ljung,

Volume 17, Issue 2, Pages (February 1950)

Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk E.Jan Irvine, John K. Marshall Gastroenterology

Volume 121, Issue 5, Pages (November 2001)

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Volume 121, Issue 2, Pages (August 2001)

Evaluation of diagnostic tests

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 122, Issue 4, Pages (April 2002)

Janusz A. Jankowski, Dawn Provenzale, Paul Moayyedi Gastroenterology

Mesalamine and relapse prevention in Crohn's disease

Michelle Maria Pietzak Gastroenterology

Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato

Volume 121, Issue 3, Pages (September 2001)

Predictors of response to infliximab in patients with Crohn's disease

Log faecal calprotectin concentration (mg/l) in the different diagnostic groups. Log faecal calprotectin concentration (mg/l) in the different diagnostic.

Volume 120, Issue 4, Pages (March 2001)

Presentation transcript:

Volume 123, Issue 2, Pages 450-460 (August 2002) Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease Jeremy A. Tibble, Gudmundur Sigthorsson, Russell Foster, Ian Forgacs, Ingvar Bjarnason Gastroenterology Volume 123, Issue 2, Pages 450-460 (August 2002) DOI: 10.1053/gast.2002.34755 Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 1 Principal symptoms for which patients were referred according to the final diagnostic group. Gastroenterology 2002 123, 450-460DOI: (10.1053/gast.2002.34755) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 2 Dot plot of fecal calprotectin levels in the different diagnostic groups. The cutoff value for normality (10 mg/L) is shown by the horizontal line. The calprotectin levels in all organic diagnostic groups except those with diabetic diarrhea differed significantly (P = 0.001 to <0.0001) from those in the IBS group. Gastroenterology 2002 123, 450-460DOI: (10.1053/gast.2002.34755) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 3 ROC for fecal calprotectin identifying patients with organic disease. At the cutoff value for normality (10 mg/L), fecal calprotectin has a sensitivity of 89% and specificity of 79% for organic disease. Gastroenterology 2002 123, 450-460DOI: (10.1053/gast.2002.34755) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 4 ROC for intestinal permeability identifying patients with organic small intestinal disease. At the cutoff value for normality (0.05), intestinal permeability has a sensitivity of 63% and specificity of 87% for organic small intestinal disease. Gastroenterology 2002 123, 450-460DOI: (10.1053/gast.2002.34755) Copyright © 2002 American Gastroenterological Association Terms and Conditions